SAN DIEGO (AP) -- Arena Pharmaceuticals Inc. said Wednesday that it filed for marketing approval for its anti-obesity pill Belviq in Switzerland.
Arena said it expects Swissmedic, the country's health agency, to accept the filing later this month and begin its review process.
The Food and Drug Administration approved Belviq on June 27, making it the first long-term prescription weight loss drug approved in the U.S. in more than a decade. European Union regulators are reviewing the drug.
Shares of Arena Pharmaceuticals lost 68 cents, or 5.8 percent, to $11.13 on Wednesday, after competitor Orexigen Therapeutics Inc. said enrollment in a study of its potentially competing experimental weight-loss drug Contrave was going more quickly than expected. Arena picked up 4 cents to $11.17 in after-hours trading.